Articles On Immuron (ASX:IMC)

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

Immuron (ASX:IMC) has announced that the US Naval Medical Research Center has received approval from the US FDA to proceed with the clinical evaluation of the new oral therapeutic targeting campylobacter and enterotoxigenic Escheric...

Little Green Pharma gets extended contract from the French government US FDA’s decision paves the way for a clinical involving Immuron’s drug Antisense Therapeutics announces new CEO   Cannabis stock Little Green Pharma (ASX:LGP) has been...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

ShareCafeTech and mining shares lead ASX 0.25% lower at close by Peter Milios   Technology and mining shares led the decline before the Easter break. For the week, the benchmark index recorded a gain of 0.6 per cent, marking its second cons...

Health care stocks have surged in early trade, up more than a per cent. Biotech company Immuron made the most of the boost, with its shares up more than 21 per cent after posting its Q3 FY23 financial figures. Global sales of its trav...

ShareCafeAus shares down 0.25% at noon as RBA warns of higher risk by Peter Milios   The Reserve Bank of Australia’s Financial Stability Review states that while the Australian financial system is strong and able to support economic activit...

Immuron (IMC) shares are rising after posting its Travelan and Protectyn sales figures for Q3 FY23 Global Q3 YTD sales of Travelan and Protectyn have risen by 239 per cent in FY23 to reach $1.46 million In Australia, sales of both pro...

ShareCafeStocks of the Hour: IMC, WMG, CPM                    Australian based and globally integrated biopharmaceutical company, Immuron (ASX:IMC) has announced that their global Q3 year-to-date sales have increased by 239% and their...

06 Apr 2023 - A snapshot of the stocks on the move featuring Immuron (ASX:IMC), Western Mines Group (ASX:WMG) and Cooper Metals (ASX:CPM).

Noxopharm plunged 45pc after scaling down its Veyonda program Rhythm Biosciences rose 25pc after saying that ColoSTAT will be presented at a prestigious gathering Immuron surged 24% as global sales rose significantly   Noxopharm (ASX:NOX)...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX is poised to open modestly lower on Thursday Tech stocks plummeted in the US overnight on rotation away from growth shares Citi and BoA predict bullish gold target prices this year   Aussie shares are set to edge modestly lower on...

The ASX is expected to slip on Thursday as eyes are once again on the Reserve Bank. The RBA is expected to deliver its financial stability review in the coming hours, ahead of the Easter long weekend. Here are some ASX-listed companie...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Cynata Therapeutics’ chief medical officer, Jolanta Airey, gives a step-by-step guide on what biotechs need to do to commence a clinical trial Which ASX biotechs have an IND submission to the FDA and will start a clinical trial soon?   Wh...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Immuron (ASX:IMC) has updated on the US Department of Defense Uniformed Services University (USU) clinical evaluation of the company's Travelan. 

Good news is bad news for the US economy Aussie benchmark goes deep into a pre-Christmas shame spiral Ho ho oh s%#$! What just happened?   The Closing Jingle Bell has rung, so that’s it until after Christmas for 2022! What a pity today’s...

Immuron’s (IMC) lands US Food and Drug Administration (FDA) approval for its investigational new drug application for its Travelan product With the approval in hand, IMC can proceed with its clinical trial assessing the safety and effica...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Dr Boreham’s Crucible By Tim Boreham ASX code: ((IIQ)) Share price: 67 cents Market cap: $59.8 million Shares on issue: 92,018,702 Chief executive officer: Dr Leearne Hinch Board: Dr Geoffrey Cumming (chair), Robert (Max) Johnston, Philip P...

Immuron (IMC) will deprioritise its SARS-COV-2 research to focus on the clinical development of its therapeutic drug candidates Immuron entered the new financial year with a newly appointed CEO at its helm, who has been working to complete...

Immuron (ASX:IMC) has announced that the US Naval Medical Research Center has received feedback from the US FDA following a review of the Investigational New Drug application for a new oral therapeutic targeting Campylobacter and ET...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Biopharmaceutical company Immuron (IMC) sees a 494 per cent increase in North American Travelan sales for FY22 Sales totalled $600,000 for the financial year, up from the $100,000 recorded in FY21 while US sales were up from the $4000 reco...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Immuron (ASX:IMC) has announced that the US Naval Medical Research Center has submitted an Investigational New Drug application to the US FDA for a new oral therapeutic targeting Campylobacter and ETEC.

Immuron’s (IMC) travellers diarrhoea preventative medication Travelan is set to be tested for efficacy to inform strategies for defence force health protection The study is being conducted by the US Department of Defense Uniformed Services...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Highlights The Australian healthcare sector includes companies engaged in biotechnology and research, food and drug retailing, health care equipment, service providers, and pharmaceuticals. On a YTD basis, the healthcare index is runni...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Things weren’t looking good ahead of the opening bell today, after a rough session for US stocks following another rise in bond yields overnight. And that bearish momentum flowed through to the ASX 200, which posted its second +1% fall in f...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week There’s so...

The Immuron Ltd (ASX: IMC) share price soared again today, trading up 16.67% at 14 cents near the market close. This follows a massive trading day as the company cemented its place as one of the best performers on the ASX yesterday with i...

Immuron (IMC) is granted a European patent for compositions and methods for treating travellers’ diarrhoea  Immuron’s Travelan is an orally administered immunotherapy that reduces the likelihood of contracting travellers’ diarrhoea – prove...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

ASX investors got back in the risk saddle on Wednesday, with steady gains across the large cap indexes and a 1.7% jump for the microcap Emerging Companies index. The catalyst appeared to be comments from US Fed Chair Jerome Powell overnight...

The Australian share market has recovered after two days of losses with Energy and Materials stocks leading the charge. The S&P/ASX 200 Index has clawed back 47 points, or 0.64 per cent, to 7437.10, making up for most of yesterday’s...

The ASX has jumped out of the blocks this morning, as expected, after two consecutive days of losses. The S&P/ASX 200 Index has risen 35.8 points, or 0.48 per cent, to 7,425.90. What’s driving the market The Nasdaq continued...

Immuron nabs $6.2m clinical research deal for US Military strength Travelan dose ECS Botanics reports record revenue of $1.5m expected for Q2 FY22 Compumedics secures first major magnetoencephalography (MEG) sale in China Immuron (ASX:IMC...

The Immuron Ltd (ASX: IMC) share price is shooting out the lights on Wednesday following a positive update from the company. At the time of writing, the biopharma company’s shares are swapping hands for 12.2 cents, up 31.18%. A clinical-st...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...